Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch
Compass Pathways (CMPS) has completed its FDA application for psilocybin therapy (COMP360) and is preparing for launch. The company expects revenue to begin late Q2 or Q3 2024, pending approval and rescheduling. It is also planning reimbursement support and patient assistance programs. Compass is confident in its commercial positioning despite competition. The company is also conducting trials for post-traumatic stress disorder.
How this was made

The 30-second read
Why it matters
The filing is a material regulatory event that could drive the stock higher if the FDA grants approval, but the timeline for revenue is delayed until late Q2/Q3 of next year, adding uncertainty.
Market read
First disclosure of the FDA filing creates a fresh catalyst for CMPS and may influence the psychedelic‑therapy sector.
What to watch
Potential competition from Usona Institute's psilocybin program and the need for state rescheduling could delay commercial rollout.
Background
Compass Pathways (NASDAQ:CMPS) announced completion of its FDA application for COMP360, a synthetic psilocybin therapy targeting treatment‑resistant depression, and outlined launch and reimbursement plans.
Ticker impact
Compass Pathways filed its FDA application for the psilocybin therapy COMP360, marking the first public disclosure of the submission.
possible upward pressure as investors price in the chance of approval, tempered by uncertainty around scheduling and reimbursement.
Regulatory filings for novel psychedelics are rare and can move biotech stocks sharply; the market will likely react positively to any progress toward approval.
Market effects
May boost sentiment for the broader psychedelic‑therapy sector and other mental‑health biotech firms.
Primarily U.S. biotech market; limited immediate effect on broader indices.
Limited to investors tracking emerging‑therapy biotech stocks worldwide.
Counterpoint
Approval risk remains high; regulatory hurdles and reimbursement uncertainty could outweigh upside.
Key entities
- companyCompass Pathways
Biotech firm developing psilocybin‑based therapies.
- regulatorFDA
U.S. Food and Drug Administration reviewing the COMP360 application.

